Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
Norris PC, Skulas-Ray AC, Riley I, Richter CK, Kris-Etherton PM, Jensen GL, Serhan CN, Maddipati KR
Scientific reports · 99 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- U.S. Department of Agriculture
- Universidad u hospital
- University of Pennsylvania
- Universidad u hospital
- Pennsylvania State University
- Universidad u hospital
- Georgia Clinical and Translational Science Alliance
- Gobierno
- National Institutes of Health
- Gobierno
- Cooperative State Research, Education, and Extension Service
- Gobierno
- National Institute of General Medical Sciences
- Gobierno
- National Center for Research Resources
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NCRR NIH HHS
- Gobierno
- NCATS NIH HHS
- Gobierno
- NIGMS NIH HHS
- Subvenciones
- National Center for Advancing Translational Sciences (UL1-TR000127); Pennsylvania State University (UL1TR000127); National Institute of General Medical Sciences (P01GM095467); National Center for Advancing Translational Sciences (TR000127); National Center for Research Resources (S10-RR-027926); National Center for Research Resources (M01-RR-010732); National Institutes of Health (M01-RR-10-732); National Institutes of Health (1s10rr027926-01); Pennsylvania State University (NIH/NCATS Grant Number UL1 TR000127); National Institutes of Health (TR000127); National Institutes of Health (UL1-TR-000127)
Según 12 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-12-17 · Sci Rep · vol. 8 · número 1 · pág. 18050
- Editorial
- Nature Portfolio
- Citado
- 103 citas · más que el 97% de estudios similares · 6.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 61 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Eicosanoids and Hypertension Pharmacology · Metabolomics and Mass Spectrometry Studies
- Palabras clave
- specialized pro-resolving mediators, omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, resolvins, lipoxins, lipopolysaccharide challenge, endotoxin, inflammation resolution, interlaboratory validation, prostaglandins, thromboxane
- MeSH
- humans, inflammation, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, endotoxins, chromatography, liquid, dose-response relationship, drug, research design, dietary supplements, adult, female, male, lipid metabolism, tandem mass spectrometry, metabolomics, metabolome, young adult, administration, intravenous, healthy volunteers
8 autores
- Paul C. Norris🇺🇸Brigham and Women's Hospital; Harvard University
- Ann C. Skulas‐Ray🇺🇸University of Arizona
- Ian R. Riley🇺🇸Brigham and Women's Hospital; Harvard University
- Chesney K. Richter🇺🇸University of Arizona
- Penny M. Kris‐Etherton🇺🇸Pennsylvania State University
- Gordon Lee Jensen🇺🇸University of Vermont
- Charles Nicholas Serhan🇺🇸 · autor de correspondenciaBrigham and Women's Hospital; Harvard University
- Krishna Rao Maddipati🇺🇸 · autor de correspondenciaWayne State University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Specialized pro-resolving mediator(s) (SPMs) are produced from the endogenous ω-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and accelerate resolution of acute inflammation. We identified specific clusters of SPM in human plasma and serum using LC-MS/MS based lipid mediator (LM) metabololipidomics in two separate laboratories for inter-laboratory validation. The human plasma cluster consisted of resolvin (Rv)E1, RvD1, lipoxin (LX)B4, 18-HEPE, and 17-HDHA, and the human serum cluster consisted of RvE1, RvD1, AT-LXA4, 18-HEPE, and 17-HDHA. Human plasma and serum SPM clusters were increased after ω-3 supplementation (triglyceride dietary supplements or prescription ethyl esters) and low dose intravenous lipopolysaccharide (LPS) challenge. These results were corroborated by parallel determinations with the same coded samples in a second, separate laboratory using essentially identical metabololipidomic operational parameters. In these healthy subjects, two ω-3 supplementation protocols (Study A and Study B) temporally increased the SPM cluster throughout the endotoxin-challenge time course. Study A and Study B were randomized and Study B also had a crossover design with placebo and endotoxin challenge. Endotoxin challenge temporally regulated lipid mediator production in human serum, where pro-inflammatory eicosanoid (prostaglandins and thromboxane) concentrations peaked by 8 hours post-endotoxin and SPMs such as resolvins and lipoxins initially decreased by 2 h and were then elevated at 24 hours. In healthy adults given ω-3 supplementation, the plasma concentration of the SPM cluster (RvE1, RvD1, LXB4, 18-HEPE, and 17-HDHA) peaked at two hours post endotoxin challenge. These results from two separate laboratories with the same samples provide evidence for temporal production of specific pro-resolving mediators with ω-3 supplementation that together support the role of SPM in vivo in inflammation-resolution in humans.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.